Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 69

1.

Effective management of refractory postcardiotomy bleeding with the use of recombinant activated factor VII.

Filsoufi F, Castillo JG, Rahmanian PB, Scurlock C, Fischer G, Adams DH.

Ann Thorac Surg. 2006 Nov;82(5):1779-83.

PMID:
17062247
2.

Is recombinant activated factor VII effective in the treatment of excessive bleeding after paediatric cardiac surgery?

Okonta KE, Edwin F, Falase B.

Interact Cardiovasc Thorac Surg. 2012 Oct;15(4):690-4. Epub 2012 Jul 18. Review.

3.
4.

Recombinant activated factor VII (NovoSeven): addition to replacement therapy in acute, uncontrolled and life-threatening bleeding.

Mayo A, Misgav M, Kluger Y, Geenberg R, Pauzner D, Klausner J, Ben-Tal O.

Vox Sang. 2004 Jul;87(1):34-40. Review.

PMID:
15260820
5.

Review of the off-label use of recombinant activated factor VII in pediatric cardiac surgery patients.

Guzzetta NA, Russell IA, Williams GD.

Anesth Analg. 2012 Aug;115(2):364-78. doi: 10.1213/ANE.0b013e31825aff10. Epub 2012 May 31. Review.

PMID:
22652310
6.

Use of recombinant activated factor VII for bleeding following operations requiring cardiopulmonary bypass.

DiDomenico RJ, Massad MG, Kpodonu J, Navarro RA, Geha AS.

Chest. 2005 May;127(5):1828-35. Review.

PMID:
15888865
7.

Recombinant factor VIIa in the treatment of bleeding.

Midathada MV, Mehta P, Waner M, Fink LM.

Am J Clin Pathol. 2004 Jan;121(1):124-37. Review.

PMID:
14750250
8.

[Recombinant activated factor VII in the postanesthetic recovery unit: review of 16 cases].

Etxániz Alvarez A, Pita Zapata E, Rama Maceiras P, Duro Tacón J, Pose Cambeiro P.

Rev Esp Anestesiol Reanim. 2006 Mar;53(3):159-62. Review. Spanish.

PMID:
16671259
9.
10.

Recombinant factor VIIa use in cardiac surgery--expanding the arsenal therapy for intractable bleeding?

Kogan A, Berman M, Stein M, Vidne BA, Raanani E.

J Cardiovasc Surg (Torino). 2004 Dec;45(6):569-71. Review.

PMID:
15746637
11.

Potential role of recombinant factor VIIa as a hemostatic agent.

Hedner U, Erhardtsen E.

Clin Adv Hematol Oncol. 2003 Feb;1(2):112-9. Review.

PMID:
16224390
12.

'Last-ditch' use of recombinant factor VIIa in patients with massive haemorrhage is ineffective.

Clark AD, Gordon WC, Walker ID, Tait RC.

Vox Sang. 2004 Feb;86(2):120-4. Review.

PMID:
15023181
13.

Recombinant activated factor VII for non-hemophiliac bleeding patients.

Uhlmann EJ, Eby CS.

Curr Opin Hematol. 2004 May;11(3):198-204. Review.

PMID:
15257021
14.

[Recombinant activated factor VII for perioperative bleeding].

López R, Aeschlimann N, Carvajal C, Lema G.

Rev Med Chil. 2009 Jun;137(6):837-43. doi: /S0034-98872009000600016. Epub 2009 Sep 4. Review. Spanish.

15.

Emerging off-label uses for recombinant activated factor VII: grading the evidence.

Enomoto TM, Thorborg P.

Crit Care Clin. 2005 Jul;21(3):611-32. Review.

PMID:
15992675
16.

Recombinant activated factor VII in cardiac surgery: a systematic review.

Warren O, Mandal K, Hadjianastassiou V, Knowlton L, Panesar S, John K, Darzi A, Athanasiou T.

Ann Thorac Surg. 2007 Feb;83(2):707-14. Review.

PMID:
17258029
17.

"Off-license" use of recombinant activated factor VII.

Ghorashian S, Hunt BJ.

Blood Rev. 2004 Dec;18(4):245-59. Review.

PMID:
15501553
18.

Safety profile of recombinant factor VIIa.

Roberts HR, Monroe DM 3rd, Hoffman M.

Semin Hematol. 2004 Jan;41(1 Suppl 1):101-8. Review.

PMID:
14872430
19.
20.

Supplemental Content

Support Center